{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:31:01Z","timestamp":1779114661961,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.068","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T08:01:05Z","timestamp":1580716865000},"page":"2307-2314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines"],"prefix":"10.1016","volume":"38","author":[{"given":"Mark R.","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Ionin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy E.","family":"Barnewall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukjoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffry D.","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Savransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.068_b0005","doi-asserted-by":"crossref","unstructured":"Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999; 281(18):1735-1745. Review. Erratum in: JAMA 2000; 283(15):1963.","DOI":"10.1001\/jama.281.18.1735"},{"issue":"5","key":"10.1016\/j.vaccine.2020.01.068_b0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1083\/jcb.200312072","article-title":"Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway","volume":"166","author":"Abrami","year":"2004","journal-title":"J Cell Biol"},{"issue":"11","key":"10.1016\/j.vaccine.2020.01.068_b0015","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0041-0101(01)00161-1","article-title":"Toxins of Bacillus anthracis","volume":"39","author":"Brossier","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2020.01.068_b0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol."},{"issue":"7002","key":"10.1016\/j.vaccine.2020.01.068_b0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/430843a","article-title":"Structural biology: anthrax hijacks host receptor","volume":"430","author":"Bann","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.068_b0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"issue":"7","key":"10.1016\/j.vaccine.2020.01.068_b0035","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vacc Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2020.01.068_b0040","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1128\/CVI.00240-12","article-title":"Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax","volume":"19","author":"Leffel","year":"2012","journal-title":"Clin Vacc Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.01.068_b0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human Anthrax Vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2020.01.068_b0050","doi-asserted-by":"crossref","unstructured":"Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19(23-24):3241\u20133247. Erratum in: Vaccine 2001; 20(3-4):635.","DOI":"10.1016\/S0264-410X(01)00411-X"},{"issue":"11","key":"10.1016\/j.vaccine.2020.01.068_b0055","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vacc Immunol"},{"issue":"37","key":"10.1016\/j.vaccine.2020.01.068_b0060","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax\u00ae (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2020.01.068_b0065","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2020.01.068_b0070","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","article-title":"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults","volume":"34","author":"Hopkins","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.068_b0075","unstructured":"CBER. 23 April 2002. Anthrax vaccines: efficacy testing and surrogate markers of immunity. U.S. Department of Health and Human Services, Food and Drug Administration. <http:\/\/www.fda.gov\/downloads \/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsC onferences\/TranscriptsMinutes\/UCM054606.pdf>."},{"issue":"5","key":"10.1016\/j.vaccine.2020.01.068_b0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/108729001753231713","article-title":"CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved","volume":"11","author":"Rankin","year":"2001","journal-title":"Antisense Nucl Acid Drug Dev"},{"key":"10.1016\/j.vaccine.2020.01.068_b0085","unstructured":"Ionin B. Development of a Guinea Pig Model for Post-Exposure Prophylaxis of Inhalation Anthrax. In: 8th Annual biodefense vaccines & therapeutics conference, Animal Model Forum, June 15; 2010."},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.068_b0090","first-page":"336","article-title":"On the histopathology of experimental anthrax in the guinea-pig","volume":"36","author":"Ross","year":"1955","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.vaccine.2020.01.068_b0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/path.1700730219","article-title":"The pathogenesis of anthrax following the administration of spores by the respiratory route","volume":"73","author":"Ross","year":"1957","journal-title":"J Pathol Bacteriol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.068_b0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/iai.52.2.454-458.1986","article-title":"Immunization studies with attenuated strains of Bacillus anthracis","volume":"52","author":"Ivins","year":"1986","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.068_b0105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.068_b0110","doi-asserted-by":"crossref","unstructured":"Savransky V, Shearer JD, Gainey MR, Sanford DC, Sivko GS, Stark GV, Li N, Ionin B, Lacy MJ, Skiadopoulos MH. Correlation between anthrax lethal toxin-neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine. 2017; 35(37):4952-4959.","DOI":"10.1016\/j.vaccine.2017.07.076"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2020.01.068_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jim.2011.12.002","article-title":"Validation and long-term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG","volume":"376","author":"Semenova","year":"2012","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2020.01.068_b0120","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.00090-06","article-title":"Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model","volume":"50","author":"Kao","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.vaccine.2020.01.068_b0125","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1128\/IAI.01289-12","article-title":"Pathology and pathophysiology of inhalational anthrax in a guinea pig model","volume":"81","author":"Savransky","year":"2013","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.068_b0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals","volume":"150","author":"Guyton","year":"1947","journal-title":"Am J Physiol"},{"issue":"8","key":"10.1016\/j.vaccine.2020.01.068_b0135","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1128\/JCM.42.8.3626-3634.2004","article-title":"MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest","volume":"42","author":"Turnbull","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.068_b0140","doi-asserted-by":"crossref","unstructured":"Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287(17):2236\u201352. Erratum in: JAMA 2002; 288(15):1849.","DOI":"10.1001\/jama.287.17.2236"},{"key":"10.1016\/j.vaccine.2020.01.068_b0145","unstructured":"Bader MS, McKinsey DS. Postexposure prophylaxis for common infectious diseases. Am Fam Physician 2013; 88(1):25-32. Review. Erratum in: Am Fam Physician. 2013; 88(10):636."},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.068_b0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3949\/ccjm.84a.15049","article-title":"Postexposure management of infectious diseases","volume":"84","author":"Bader","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.vaccine.2020.01.068_b0155","unstructured":"CDER and CBER. Product Development Under the Animal Rule: Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration. October 2015. <https:\/\/www.fda.gov\/media\/88625\/download>."},{"key":"10.1016\/j.vaccine.2020.01.068_b0160","unstructured":"CBER. Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule. Briefing Document for the Vaccines and Related Biological Products Advisory Committee Meeting, November 16, 2010. <https:\/\/wayback.archive-it.org\/7993\/20170113080506\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM232400.pdf>."},{"issue":"11","key":"10.1016\/j.vaccine.2020.01.068_b0165","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1128\/IAI.70.11.6231-6241.2002","article-title":"Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs","volume":"70","author":"Altboum","year":"2002","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20301067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:28Z","timestamp":1759401628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20301067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20301067"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}